Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ENROLLING BY INVITATION

NCT05248659

PHASE2/PHASE3

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

View on ClinicalTrials.gov

Summary

To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN

Official title: A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

600

Start Date

2022-04-05

Completion Date

2029-12-31

Last Updated

2026-05-05

Healthy Volunteers

Conditions

Immunoglobulin A Nephropathy

Interventions

DRUG

Sibeprenlimab 400 mg s.c. Q4weeks

Sibeprenlimab 400 mg s.c. q 4 weeks

Inclusion Criteria: * Subjects who completed Trial 417-201-00007 (at least 20 of the 26 doses over a 2-year duration and the end-of-trial visit) or Trial VIS649-201 (at least 9 of the 12 doses over a 1-year duration and the end-of-trial visit) without safety concerns and who, in the opinion of the investigator, could potentially benefit from treatment with sibeprenlimab for IgAN. * Ability to provide written, informed consent prior to initiation of any trial-specific procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial. Exclusion Criteria: * Subjects who have not completed participation in Trials 417-201-00007 or VIS649-201. * Subjects with treatment-limiting AEs during Trials 417-201-00007 or VIS649-201 considered related to IMP per investigator judgement. * Noncompliance, due to subject's repeated failure to follow trial procedures during the course of their participation in Trials 417-201-00007 and VIS649-201 (eg, subjects deemed to be noncompliant with the visit schedule, trial assessments, or treatment regimen). The medical monitor should be contacted if the investigator is unsure of a subject's eligibility. * Subjects who have a positive pregnancy test result prior to receiving IMP. * Heterosexually active biological males or subjects of childbearing potential, or their partners, who do not agree to adhere to contraceptive requirements from the time of consent through the end of the subject's participation in the trial and an additional 90 days (biological male subjects) or 30 days (biological female subjects) thereafter. * Biological male subjects who do not agree to avoid donation of sperm from the time of consent through the end of the subject's participation in the trial and an additional 90 days thereafter. * Subject has nephrotic syndrome, defined for this purpose as 24-hour urine protein \> 3.5 g with concurrent hypoalbuminemia (serum albumin \< 2.5 g/dL), hyperlipidemia (total cholesterol \> 350 mg/dL), and edema. Subjects with isolated nephrotic range proteinuria (\> 3.5 g/day) will be eligible. * Subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, rheumatologic, blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or ongoing malignancy. History of minor skin cancers (not including melanoma) or surgically treated, limited cervical carcinomas (ie, carcinoma in situ) are not exclusionary. * History of a previous hypersensitivity or severe allergic reaction with generalized urticaria, angioedema or anaphylaxis to any of the ingredients of the sibeprenlimab SC injection formulation. * Subject has a body mass index \< 16 kg/m\^2. * Subject has received an organ transplant (ie, solid or a bone marrow or hematologic stem cell transplantation). * Subject is currently receiving, or has received within 16 weeks prior to enrollment, systemic immunosuppressive therapy (ie, steroids such as targeted release budesonide, complement inhibitors, mycophenolate, rituximab). Note: topical, ophthalmic, rectal, intra-articular, inhaled corticosteroids, and short courses of oral/intravenous steroids (\<= 14 days) are allowed.

Locations (158)

Clinical Research Site #336

Birmingham, Alabama, United States

Clinical Research Site #325

Los Angeles, California, United States

Clinical Research Site #370

Palo Alto, California, United States

Clinical Research Site #330

Denver, Colorado, United States

Clinical Research Site #323

Lauderdale Lakes, Florida, United States

Clinical Research Site #373

Atlanta, Georgia, United States

Clinical Research Site #356

Lawrenceville, Georgia, United States

Clinical Research Site #369

Boston, Massachusetts, United States

Clinical Research Site #331

Worcester, Massachusetts, United States

Clinical Research Site #320

Shelby, Michigan, United States

Clinical Research Site #346

Great Neck, New York, United States

Clinical Research Site #350

Columbus, Ohio, United States

Clinical Research Site #374

Dakota Dunes, South Dakota, United States

Clinical Research Site #324

Houston, Texas, United States

Clinical Research Site #361

Milwaukee, Wisconsin, United States

Clinical Research Site #800

Buenos Aires, Argentina

Clinical Research Site #802

Buenos Aires, Argentina

Clinical Research Site #801

Córdoba, Argentina

Clinical Research Site #003

Garran, Australian Capital Territory, Australia

Clinical Research Site #013

Concord, New South Wales, Australia

Clinical Research Site #014

Kogarah, New South Wales, Australia

Clinical Research Site

New Lambton Heights, New South Wales, Australia

Clinical Research Site #006

Saint Leonards, New South Wales, Australia

Clinical Research Site #012

Adelaide, South Australia, Australia

Clinical Research Site #001

Fitzroy, Victoria, Australia

Clinical Research Site #010

St Albans, Victoria, Australia

Clinical Research Site #011

Liverpool, Australia

Clinical Research Site #401

Genk, Belgium

Clinical Research Site #405

Genk, Belgium

Clinical Research Site #820

Recife, Pernambuco, Brazil

Clinical Research Site #824

Porto Alegre, Rio Grande do Sul, Brazil

Clinical Research Site #821

Joinville, Santa Catarina, Brazil

Clinical Research Site #822

São José do Rio Preto, So Paulo, Brazil

Clinical Research Site #831

Rio de Janeiro, Brazil

Clinical Research Site #823

São Paulo, Brazil

Clinical Research Site #300

Calgary, Alberta, Canada

Clinical Research Site #305

Scarborough Village, Ontario, Canada

CISSS de la Monteregie centre-Centre de recherche Hopital Charles Lemoyne

Greenfield Park, Quebec, Canada

Clinical Research Site #036

Beijing, Beijing Municipality, China

Clinical Research Site #020

Beijing, Beijing Municipality, China

Clinical Research Site #028

Guangzhou, Guangdong, China

Clinical Research Site #044

Changsha, Hunan, China

Clinical Research Site #030

Wuxi, Jiangsu, China

Clinical Research Site #022

Nanchang, Jiangxi, China

Clinical Research Site #026

Jinan, Shandong, China

Clinical Research Site #038

Chengdu, Sichuan, China

Clinical Research Site #025

Yibin, Sichuan, China

Clinical Research Site #413

Split, Croatia

Clinical Research Site #414

Zagreb, Croatia

Vseobecna fakultni nemocnice v Praze

Prague, Czechia

Clinical Research Site #433

Grenoble, Auvergne-Rhône-Alpes, France

Clinical Research Site #430

Nîmes, Gard, France

Clinical Research Site #432

Nantes, Loire-Atlantique, France

Clinical Research Site #439

Limoges, New Aquitaine, France

Clinical Research Site #434

Sr Priest En Jarez, Pays de la Loire Region, France

Clinical Research Site #455

Mainz, Rhineland-Palatinate, Germany

Universitaetsklinikum Carl Gustav Carus

Dresden, Saxony, Germany

Clinical Research Site #472

Heraklion, Greece

Clinical Research Site #064

Hong Kong, New Territories, Hong Kong

Clinical Research Site #060

Hong Kong, Hong Kong

Clinical Research Site #061

Hong Kong, Hong Kong

Clinical Research Site #062

Kowloon, Hong Kong

Clinical Research Site #063

Shatin, Hong Kong

Clinical Research Site #482

Pécs, Baranya, Hungary

Clinical Research Site #081

Hyderabad, Deccan, India

Clinical Research Site #073

Ahmedabad, Gujarat, India

Clinical Research Site #070

Nadiād, Gujarat, India

Clinical Research Site #087

Bengaluru, Karnataka, India

Clinical Research Site #079

Manipal, Karnataka, India

Clinical Research Site #071

Kozhikode, Kerala, India

Clinical Research Site #074

Thiruvananthapuram, Kerala, India

Clinical Research Site #084

Pune, Maharashtra, India

Clinical Research Site #075

New Delhi, National Capital Territory of Delhi, India

Clinical Research Site #077

Chandigarh, Punjab, India

Clinical Research Site #080

Rajipet, Tamil Nadu, India

Clinical Research Site #078

Afzalganj, Telangana, India

Clinical Research Site #076

Lucknow, Uttar Pradesh, India

Clinical Research Site #494

Ashkelon, Israel

Tel Aviv University Sackler School of Medicine - Meir Medical Center (MMC) (Meir Hospital)

Kfar Saba, Israel

Clinical Research Site #495

Nahariya, Israel

Clinical Research Site #493

Petach Tiqwa, Israel

Clinical Research Site #512

Bologna, Italy

Clinica Nefrologica, Dialisi e Trapianto, IRCCS Ospedale Policlinico San Martino

Genova, Italy

Clinical Research Site #509

Pavia, Italy

Clinical Research Site #507

Piacenza, Italy

Clinical Research Site #705

Nagoya, Aichi-ken, Japan

Clinical Research Site #709

Toyoake-shi, Aichi-ken, Japan

Clinical Research Site #700

Chiba, Chiba, Japan

Clinical Research Site #707

Urayasu-shi, Chiba, Japan

Clinical Research Site #724

Kobe, Hyōgo, Japan

Clinical Research Site #708

Tsukuba, Ibaraki, Japan

Clinical Research Site #714

Kawasaki-shi, Kanagawa, Japan

Clinical Research Site #713

Kashihara, Nara, Japan

Clinical Research Site #717

Yufu, Oita Prefecture, Japan

Clinical Research Site #715

Bunkyo, Tokyo, Japan

Clinical Research Site #727

Nerima-ku, Tokyo, Japan

Clinical Research Site #703

Fukuoka, Japan

Clinical Research Site #712

Minatoku, Japan

Clinical Research Site #716

Miyazaki, Japan

Clinical Research Site #726

Tochigi, Japan

And 58 more locations on ClinicalTrials.gov